View in EDS

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Authors: Li C; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Madan RA; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee MJ; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee S; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Sato N; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Rastogi S; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Shrestha R; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, Virginia, USA., Goswami M; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Donahue RN; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Baj A; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Seo CCY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Terrigino NT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Bright JR; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Hennigan ST; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., King IM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Trostel SY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Fenimore JM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Liu Y; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA., Calzone KA; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA., Schlom J; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Gulley JL; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Dahut WL; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Figg WD; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Sowalsky AG; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee JM; Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Karzai F; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA fatima.karzai@nih.gov.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Mar 25; Vol. 14 (3). Date of Electronic Publication: 2026 Mar 25.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41881502
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+C%22">Li C</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Madan+RA%22">Madan RA</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Lee+MJ%22">Lee MJ</searchLink>; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Lee+S%22">Lee S</searchLink>; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Sato+N%22">Sato N</searchLink>; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Rastogi+S%22">Rastogi S</searchLink>; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Shrestha+R%22">Shrestha R</searchLink>; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Aragon-Ching+JB%22">Aragon-Ching JB</searchLink>; Inova Schar Cancer Institute, Fairfax, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Goswami+M%22">Goswami M</searchLink>; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Donahue+RN%22">Donahue RN</searchLink>; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Cordes+LM%22">Cordes LM</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Baj+A%22">Baj A</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Seo+CCY%22">Seo CCY</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Terrigino+NT%22">Terrigino NT</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Bright+JR%22">Bright JR</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Hennigan+ST%22">Hennigan ST</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22King+IM%22">King IM</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Trostel+SY%22">Trostel SY</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Fenimore+JM%22">Fenimore JM</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Calzone+KA%22">Calzone KA</searchLink>; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Schlom+J%22">Schlom J</searchLink>; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Gulley+JL%22">Gulley JL</searchLink>; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Dahut+WL%22">Dahut WL</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Figg+WD%22">Figg WD</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Sowalsky+AG%22">Sowalsky AG</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Lee+JM%22">Lee JM</searchLink>; Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Karzai+F%22">Karzai F</searchLink>; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA fatima.karzai@nih.gov.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2026 Mar 25; Vol. 14 (3). <i>Date of Electronic Publication: </i>2026 Mar 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41881502
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2025-014365
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li C
      – PersonEntity:
          Name:
            NameFull: Madan RA
      – PersonEntity:
          Name:
            NameFull: Lee MJ
      – PersonEntity:
          Name:
            NameFull: Lee S
      – PersonEntity:
          Name:
            NameFull: Sato N
      – PersonEntity:
          Name:
            NameFull: Rastogi S
      – PersonEntity:
          Name:
            NameFull: Shrestha R
      – PersonEntity:
          Name:
            NameFull: Aragon-Ching JB
      – PersonEntity:
          Name:
            NameFull: Goswami M
      – PersonEntity:
          Name:
            NameFull: Donahue RN
      – PersonEntity:
          Name:
            NameFull: Cordes LM
      – PersonEntity:
          Name:
            NameFull: Baj A
      – PersonEntity:
          Name:
            NameFull: Seo CCY
      – PersonEntity:
          Name:
            NameFull: Terrigino NT
      – PersonEntity:
          Name:
            NameFull: Bright JR
      – PersonEntity:
          Name:
            NameFull: Hennigan ST
      – PersonEntity:
          Name:
            NameFull: King IM
      – PersonEntity:
          Name:
            NameFull: Trostel SY
      – PersonEntity:
          Name:
            NameFull: Fenimore JM
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Calzone KA
      – PersonEntity:
          Name:
            NameFull: Schlom J
      – PersonEntity:
          Name:
            NameFull: Gulley JL
      – PersonEntity:
          Name:
            NameFull: Dahut WL
      – PersonEntity:
          Name:
            NameFull: Figg WD
      – PersonEntity:
          Name:
            NameFull: Sowalsky AG
      – PersonEntity:
          Name:
            NameFull: Lee JM
      – PersonEntity:
          Name:
            NameFull: Karzai F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 03
              Text: 2026 Mar 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1